198 related articles for article (PubMed ID: 27146933)
1. Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment.
Liang IC; Wang K; Chien HW; Lin SY
Indian J Ophthalmol; 2016 Mar; 64(3):222-4. PubMed ID: 27146933
[TBL] [Abstract][Full Text] [Related]
2. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
3. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
Jackson TL; Regillo CD; Girach A; Dugel PU;
Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
[TBL] [Abstract][Full Text] [Related]
4. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
Modi YS; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
[TBL] [Abstract][Full Text] [Related]
5. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.
Katz RS
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(3):239-42. PubMed ID: 24708167
[TBL] [Abstract][Full Text] [Related]
6. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
[TBL] [Abstract][Full Text] [Related]
7. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
[TBL] [Abstract][Full Text] [Related]
8. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.
Dugel PU; Regillo C; Eliott D
Am J Ophthalmol; 2015 Jul; 160(1):94-9.e1. PubMed ID: 25818925
[TBL] [Abstract][Full Text] [Related]
10. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
[TBL] [Abstract][Full Text] [Related]
11. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
Abou Ltaif S; Herbert L
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
[TBL] [Abstract][Full Text] [Related]
12. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
[TBL] [Abstract][Full Text] [Related]
13. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
[TBL] [Abstract][Full Text] [Related]
14. Lamellar macular hole after intravitreal ocriplasmin injection.
Chod RB; Goodrich C; Saxena S; Akduman L
BMJ Case Rep; 2015 Jan; 2015():. PubMed ID: 25576512
[TBL] [Abstract][Full Text] [Related]
15. Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
Jackson TL; Verstraeten T; Duchateau L; Lescrauwaet B
Acta Ophthalmol; 2017 Dec; 95(8):e740-e745. PubMed ID: 28133919
[TBL] [Abstract][Full Text] [Related]
16. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
[TBL] [Abstract][Full Text] [Related]
17. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
Luttrull JK
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
[TBL] [Abstract][Full Text] [Related]
18. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
[TBL] [Abstract][Full Text] [Related]
19. Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography.
Steel DH; Parkes C; Papastavrou VT; Avery PJ; El-Ghrably IA; Habib MS; Sandinha MT; Smith J; Stannard KP; Vaideanu-Collins D; Hillier RJ
Eye (Lond); 2016 May; 30(5):740-5. PubMed ID: 26965018
[TBL] [Abstract][Full Text] [Related]
20. Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting.
Wertheimer C; Haritoglou C; Laubichler P; Wolf A; Kaessmann K; Schumann RG; Priglinger S; Mayer WJ
Ophthalmologica; 2018; 239(1):11-18. PubMed ID: 28954271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
